遗传性痉挛性截瘫市场：按类型、治疗、给药途径、分销管道、患者类型和地区划分

遗传性痉挛性截瘫市场规模预计在 2025 年达到 1.814 亿美元，预计到 2032 年将达到 4.568 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 7.2%。

遗传性痉挛性截瘫 (HSP) 是一组多样化的遗传性神经系统疾病，其特征是由于皮质脊髓束轴突退化导致下肢进行进行性无力和痉挛。全球遗传性痉挛性截瘫市场包括药物介入、医疗设备、诊断工具和治疗服务，旨在管理这种复杂的疾病，全球每 10 万人中约有 3-10 人患有此病。 HSP 已鑑定出 80 多种基因亚型，分为纯基因亚型和复杂基因亚型，其显着的临床异质性需要个人化的治疗方法。基因检测的进步、对病理生理学理解的加深以及新治疗方法的出现，包括基因疗法和新型药物干预，正在迅速改变市场格局。虽然目前的治疗模式主要着重于使用抗惊厥药物、物理治疗和辅助器具进行症状管理，但研究方向越来越强调疾病修正治疗。

市场动态

全球遗传性痉挛性截瘫市场成长的关键驱动力是提高疾病意识和改善诊断能力，特别是透过先进的基因检测技术，可以早期且准确地识别 HSP 亚型。已开发国家医疗保健支出的增加，加上对罕见疾病研发的投资增加，大大推动了发展，製药和生物技术公司投入大量资源开发标靶治疗。此外，预计在分析期内，研发的增加加上监管部门的核准将推动市场扩张。例如，2025 年 4 月 28 日，专注于开发罕见神经系统疾病治疗方法的临床阶段基因治疗公司 BlackfinBio Ltd. 宣布，美国食品药物管理局(FDA) 已核准其新药临床实验(IND) 申请，对其新型腺结合病毒(AAV) 基因疗法 BFB-101 进行 1/2 期临床试验，用于儿童 477 型截瘫性基因 (SPGSPGSPGS 37)。 SPG47 是一种罕见的体染色体隐性神经系统疾病，其特征是儿童进行性下肢痉挛、发育迟缓和智能障碍。

本次调查的主要特点

• 本报告对全球遗传性痉挛性截瘫市场进行了详细分析，并以 2024 年为基准年，提供了预测期（2025-2032 年）的市场规模（百万美元）和年复合成长率（CAGR%）。
• 它还强调了各个领域的潜在商机，并说明了针对该市场的引人注目的投资提案。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、业绩和策略等参数，概述了全球遗传性痉挛性截瘫市场的主要企业。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、最新策略、市场扩张和行销策略做出明智的决策。
• 全球遗传性痉挛性截瘫市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员将透过全球遗传性痉挛性截瘫市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章：市场动态、法规与趋势分析

• 市场动态
• 驱动程式
• 抑制因素
• 机会
• 影响分析
• 监管情景
• PEST分析
• 产业趋势
• 流行病学
• 治疗方案分析
• 赎回情景
• 疾病意识计划
• 管道分析
• 科技

4. 全球遗传性痉挛性截瘫市场（依类型），2020 年至 2032 年

• 介绍
• 纯的
• 复杂的

5. 2020 年至 2032 年遗传性痉挛性截瘫治疗的全球市场

• 介绍
• 肌肉鬆弛剂
• Baclofen
• 疼痛管理
• Gabapentin或Pregabalin
• 苯二氮平类药物
• Diazepam
• 氯硝西泮
• 肉毒桿菌注射
• 其他（抗胆碱药物等）

6. 2020 年至 2032 年按给药途径分類的全球遗传性痉挛性截瘫市场

• 介绍
• 口服
• 肠外

7. 2020 年至 2032 年全球遗传性痉挛性截瘫市场（依通路划分）

• 介绍
• 医院药房
• 零售药局
• 网路药局

8. 全球遗传性痉挛性截瘫市场（依患者型态），2020 年至 2032 年

• 介绍
• 成人
• 孩子们

9. 全球遗传性痉挛性截瘫市场（依分销管道划分），2020 年至 2032 年

• 介绍
• 网路药局
• 零售药局
• 医院药房

第 10 章。 2021-2032 年全球遗传性痉挛性截瘫市场（按地区划分）价值（百万美元）

• 介绍
• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第十一章竞争格局

• Teva Pharmaceuticals USA, Inc.
• Amneal Pharmaceuticals LLC
• Piramal Pharma Limited（PPL）
• Camber Pharmaceuticals, Inc.
• ANI Pharmaceuticals, Inc.
• Nexus Pharmaceuticals, LLC
• AdvaCare Pharma
• Pfizer Inc.
• Genentech, Inc.（F. Hoffmann-La Roche AG）
• AbbVie Inc.
• Merz Pharmaceuticals, LLC.
• Ipsen Biopharmaceuticals, Inc.
• Other Prominent Players

第 12 章分析师建议

• 机会
• 一致的机会地图

第十三章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Hereditary Spastic Paraplegia Market is estimated to be valued at USD 181.4 Mn in 2025 and is expected to reach USD 456.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Hereditary spastic paraplegia (HSP) represents a diverse group of inherited neurological disorders characterized by progressive weakness and spasticity of the lower limbs, stemming from degeneration of corticospinal tract axons. The global hereditary spastic paraplegia market encompasses pharmaceutical interventions, medical devices, diagnostic tools, and therapeutic services designed to manage this complex condition affecting approximately 3-10 individuals per 100,000 worldwide. With over 80 identified genetic subtypes classified as either pure or complicated forms, HSP presents significant clinical heterogeneity that drives demand for personalized treatment approaches. The market landscape is evolving rapidly due to advancing genetic testing capabilities, improved understanding of disease pathophysiology, and emerging therapeutic modalities including gene therapy and novel pharmacological interventions. Current treatment paradigms primarily focus on symptom management through antispastic medications, physical therapy, and assistive devices, while research pipelines increasingly emphasize disease-modifying therapies.

Market Dynamics

The global hereditary spastic paraplegia market growth is primarily driven by increasing disease awareness and improved diagnostic capabilities, particularly through advanced genetic testing technologies that enable earlier and more accurate identification of HSP subtypes. Rising healthcare expenditure in developed nations, coupled with growing investment in rare disease research and development, significantly propels market expansion as pharmaceutical companies and biotechnology firms allocate substantial resources toward developing targeted therapies. Moreover, increasing research and development coupled with regulatory approval is expected to augment the market over the analysis period. For instance, on April 28, 2025, BlackfinBio Ltd, a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases, announced that the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for a Phase 1/2 clinical trial of its novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47). SPG47 is a rare, autosomal-recessive, neurological disorder characterized by progressive lower-limb spasticity, developmental delays and intellectual disability in children.

Key Features of the Study

• This report provides in-depth analysis of the global hereditary spastic paraplegia market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hereditary spastic paraplegia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Piramal Pharma Limited (PPL), Camber Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., Nexus Pharmaceuticals, LLC, AdvaCare Pharma, Pfizer Inc., Genentech, Inc. (F. Hoffmann-La Roche AG), AbbVie Inc., Merz Pharmaceuticals, LLC., Ipsen Biopharmaceuticals, Inc., and Other Prominent Players.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global hereditary spastic paraplegia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary spastic paraplegia market.

Market Segmentation

• Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Pure
  • Complicated
• Therapeutics Insights (Revenue, USD Mn, 2020 - 2032)
  • Muscle Relaxants
  • Baclofen
  • Tizanidine
  • Dantrolene
  • Pain Management
  • Gabapentin or Pregabalin
  • Benzodiazepines
  • Diazepam
  • Clonazepam
  • Botulinum Toxin Injections
  • Others (Anticholinergic medications, etc.)
• Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
  • Oral
  • Parenteral
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Patient Demographics Insights (Revenue, USD Mn, 2020 - 2032)
  • Adults
  • Pediatrics
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online Pharmacies
  • Retail Pharmacies
  • Hospitals Pharmacy
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Teva Pharmaceuticals USA, Inc.
  • Amneal Pharmaceuticals LLC
  • Piramal Pharma Limited (PPL)
  • Camber Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • Nexus Pharmaceuticals, LLC
  • AdvaCare Pharma
  • Pfizer Inc.
  • Genentech, Inc. (F. Hoffmann-La Roche AG)
  • AbbVie Inc.
  • Merz Pharmaceuticals, LLC.
  • Ipsen Biopharmaceuticals, Inc.
  • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Hereditary Spastic Paraplegia Market, By Type
  • Global Hereditary Spastic Paraplegia Market, By Therapeutics
  • Global Hereditary Spastic Paraplegia Market, By Route of Administration
  • Global Hereditary Spastic Paraplegia Market, By Distribution Channel
  • Global Hereditary Spastic Paraplegia Market, By Patient Demographics
  • Global Hereditary Spastic Paraplegia Market, By Distribution Channel
  • Global Hereditary Spastic Paraplegia Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• PEST Analysis
• Industry Trends
• Epidemiology
• Treatment Option Analysis
• Reimbursement Scenario
• Disease Awareness Programs
• Pipeline Analysis
• Technology Landscape

4. Global Hereditary Spastic Paraplegia Market, By Type, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pure
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Complicated
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Hereditary Spastic Paraplegia Market, By Therapeutics, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Muscle Relaxants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Baclofen
  • Tizanidine
  • Dantrolene
• Pain Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Gabapentin or Pregabalin
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Diazepam
• Clonazepam
• Botulinum Toxin Injections
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Anticholinergic medications, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Hereditary Spastic Paraplegia Market, By Route of Administration, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Hereditary Spastic Paraplegia Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Hereditary Spastic Paraplegia Market, By Patient Demographics, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Pediatrics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Hereditary Spastic Paraplegia Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Hospitals Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Hereditary Spastic Paraplegia Market, By Region, 2021 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2032, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Teva Pharmaceuticals USA, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amneal Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Piramal Pharma Limited (PPL)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Camber Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ANI Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Nexus Pharmaceuticals, LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AdvaCare Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Genentech, Inc. (F. Hoffmann-La Roche AG)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merz Pharmaceuticals, LLC.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ipsen Biopharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Other Prominent Players
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us